Interactive Voice Response Telephone Technology for the Treatment of Smoking in Patients With Heart Disease

Study acronym: IVR
StatusCompleted
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Phase: Phase 2 to Not applicablev9 Show 4 more changesShow less
    • Results first posted: Jun 30, 2026
    • Primary endpoint revised
    • Enrollment target: 442 to 440
    • Secondary endpoints: 4 to 2
  2. Primary completion date changed from estimate of Dec 2009 to Feb 2011v8 Show 5 more changesShow less
    • Primary endpoints: 2 to 1
    • Trial status: Active, Not Recruiting to Completed
    • Enrollment target: estimated 476 to confirmed 442
    • Study completion date changed from estimate of Dec 2010 to Feb 2011
    • Secondary endpoints: 3 to 4
  3. Trial status: Recruiting to Active, Not Recruiting
    • Study description revised
    • Site details revised
    v7
  4. 2 versions Re-verified since Oct 28, 2009, no change to tracked fieldsv5-v6
  5. Primary endpoints revised (2)v4 Show 4 more changesShow less
    • Primary completion date: Dec 2009
    • Interventions: Interactive Voice Response (Behavioral), Usual care (Behavioral) to Interactive Voice Response (Behavioral)
    • Secondary endpoints revised (3)
    • Study arms: 0 to 2
Show 2 earlier versionsHide 2 earlier versions
  1. Study completion date: Dec 2008 to Dec 2010
    • Collaborator revised
    v3
  2. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A randomized control trial is planned to evaluate an interactive voice response (IVR) mediated follow-up and triage system, against usual care, to help smokers hospitalized with Coronary Heart Disease (CHD) to quit smoking. The investigators hypothesize that compared to usual care, participants in the IVR group will; a) have a significantly higher 7-day point prevalence abstinence rate at 26 and 52 weeks after hospital discharge, b) will have a higher rate of continuous abstinence at 26 and 52 weeks after hospital discharge, c) will use a greater number of proven effective interventions over time, and d) will develop greater self-efficacy with respect to smoking cessation, over time.
Trial Details
NCT Number NCT00449852
Lead Sponsor Ottawa Heart Institute Research Corporation
Collaborators: Heart and Stroke Foundation of Ontario
Conditions
(from sponsor)		 Coronary Artery Disease
Related terms Coronary Artery Disease, Smoking Cessation
Enrollment 440 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov